Myocardial Infarction News and Research

RSS

LUMEDX receives ACC-NCDR ACTION Registry-GWTG software vendor certification

The American College of Cardiology has certified LUMEDX, a leading provider of integrated cardiovascular imaging and information systems, as an ACC-NCDR ACTION Registry-GWTG software vendor. The new ACC-NCDR ACTION Registry-GWTG is a unified registry collecting data for patients with acute myocardial infarction. LUMEDX’s Export to ACTION Registry-GWTG solution collects data at the point of care and submits it electronically to the ACC-NCDR, streamlining registry participation.

17 Dec 2009

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

St. Jude Medical, Inc. applauds the updated level of evidence for Fractional Flow Reserve (FFR)-guided treatment in the Guidelines on Percutaneous Coronary Intervention (PCI).

17 Dec 2009

Intensive medical therapy may benefit patients with asymptomatic plaque buildup

Intensive medical therapy, including aggressive control of blood pressure and cholesterol levels, for patients with asymptomatic plaque buildup in their carotid arteries (which supply blood to the brain) appears to be associated with reduced rates of cardiovascular events and reduced risk of microemboli (microscopic-sized blood clots) in the brain arteries, according to a report posted online today that will appear in the February 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

15 Dec 2009

Special issue focuses on cardiovascular disease prevention and outcomes

Emerging research on cardiovascular risk factors and treatment effects are helping clinicians gain a better understanding of which patients are most likely to benefit from close monitoring, lifestyle changes and/or additional therapeutic interventions.

14 Dec 2009

Phosphatases can prevent inflammation and formation of blood clots

Polyphosphate from blood platelets plays a key role in inflammation and the formation of blood clots, scientists from the Swedish medical university Karolinska Institutet have shown. The study, which is presented in the prestigious scientific journal Cell, describes how this mechanism can be used in treatment.

11 Dec 2009

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.

9 Dec 2009

Progenitor-cell therapy can reduce risk of another heart attack

Cells from heart attack survivors' own bone marrow reduced the risk of death or another heart attack when they were infused into the affected artery after successful stent placement, according to research reported in the American Heart Association journal Circulation: Heart Failure.

9 Dec 2009

Generic erosion of premium-priced branded agents to offset sales of new agents

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

8 Dec 2009

Atrium Medical commences enrollment in its INFUSE AMI trial

Atrium Medical Corporation announced that the 1st patient was enrolled in the INFUSE AMI trial. INFUSE AMI is a multi-center, multi-national, prospective, randomized, single blind trial examining how patients with heart attacks are treated. The study's aim is to help determine the best way to treat patients with an acute anterior wall myocardial infarction (acute MI) with ST segment elevation, commonly referred to as STEMIs.

7 Dec 2009

New findings shed light on heart attack symptoms

Researchers at Texas Health Presbyterian Hospital Dallas are investigating what symptoms could help doctors better spot heart attacks and if certain symptoms might indicate different types of heart attacks.

5 Dec 2009

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

By measuring the total gene activity in organs relevant for coronary artery disease (CAD), scientists at the Swedish medical university Karolinska Institutet have identified a module of genes that is important for the recruitment of white blood cells into the atherosclerotic plaque.

4 Dec 2009

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Isis Pharmaceuticals, Inc. announced today that it has added two new drugs to its development pipeline, ISIS-FXIRx and ISIS-SMNRx.

4 Dec 2009

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

Research: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database

4 Dec 2009

MDK to distribute China Sky One Medical's AMI Diagnostic Kit and Human Urinary Albumin Elisa Kit

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has engaged Guangdong Mediacy Kind Medical Devices Industry Service Company ("MDK") to serve as its exclusive sales agent for the Company's AMI Diagnostic Kit and Human Urinary Albumin Elisa Kit in Southeast Asia.

1 Dec 2009

European Commission and the EMEA approve Angiox in primary PCI for STEMI

The Medicines Company announced today that it has received European approval for the use of Angiox® (bivalirudin) as an anticoagulant in patients with heart attacks (so-called ST-segment elevation myocardial infarction (STEMI)) undergoing emergency heart procedures called primary percutaneous coronary intervention (PCI).

1 Dec 2009

European Commission approves MICARDIS medication for CV protection

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

27 Nov 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

Study finds no significant difference in hospital angioplasty volume and death rates in patients with myocardial infarction

A study based on a contemporary registry of patients with myocardial infarction (heart attack) indicates that even though hospitals that perform a higher number of angioplasties are more likely to follow evidence-based guidelines and have shorter times to the angioplasty procedure, there appears to be no significant difference in outcomes such as length of hospital stay or risk of death, according to a study in the November 25 issue of JAMA.

25 Nov 2009

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.

24 Nov 2009

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Merck said today that Travis County, Texas District Court Judge Scott H. Jenkins granted Merck's motion for summary judgment, dismissing all claims in a VIOXX-related lawsuit filed on behalf of the State of Texas.

23 Nov 2009

Myocardial Infarction News and Research

LUMEDX receives ACC-NCDR ACTION Registry-GWTG software vendor certification

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

Intensive medical therapy may benefit patients with asymptomatic plaque buildup

Special issue focuses on cardiovascular disease prevention and outcomes

Phosphatases can prevent inflammation and formation of blood clots

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

Progenitor-cell therapy can reduce risk of another heart attack

Generic erosion of premium-priced branded agents to offset sales of new agents

Atrium Medical commences enrollment in its INFUSE AMI trial

New findings shed light on heart attack symptoms

Findings suggest severity of atherosclerosis depends on the rate of white blood cell migration

ISIS-FXIRx and ISIS-SMNRx included in Isis Pharmaceuticals' development pipeline

Sulphonylureas, an antidiabetic drug, carries greater risk of heart failure and death compared to metformin

MDK to distribute China Sky One Medical's AMI Diagnostic Kit and Human Urinary Albumin Elisa Kit

European Commission and the EMEA approve Angiox in primary PCI for STEMI

European Commission approves MICARDIS medication for CV protection

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Study finds no significant difference in hospital angioplasty volume and death rates in patients with myocardial infarction

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

Texas Court dismisses all claims against Merck in VIOXX-related lawsuit

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News